12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
11:54 , Apr 18, 2019 |  BC Innovations  |  Translation in Brief

Blocking phages to prevent wound infections

Stanford researchers have shown that immunizing against a bacteriophage found in Pseudomonas aeruginosa prevented the bacteria from infecting chronic wounds. The findings offering a prophylactic alternative to using antibiotics to treat surgical and other wounds...
19:24 , Apr 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Targeting a Pseudomonas phage protein to prevent chronic wounds

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas Patient sample and mouse studies suggest inhibiting or immunizing against Pf4 coaB could help prevent Pseudomonas aeruginosa infections in chronic wounds. In patients with chronic wounds infected by P....
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Akers Biosciences, Jai Capital deal

Akers granted Jai non-exclusive rights to commercialize four of Akers' rapid tests in India. The products are Akers' PIFA Heparin / PF4 test to detect heparin-induced thrombocytopenia (HIT) antibodies; PIFA Dengue Fever screening test for...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Carolus, Alpha-1 Foundation deal

Carolus partnered with the not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary to characterize human biological samples for the presence of chemokine CC motif ligand 5 ( RANTES ; CCL5 )- platelet factor 4 ( PF4...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Platelet factor 4 (PF4; CXCL4) In vitro and mouse studies suggest small molecule mimetics of PF4 could help treat malaria. In vitro, the...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Platelet factor 4 (PF4; CXCL4) Cell culture studies suggest CXCL4 could help prevent HIV replication. In a cell culture assay of HIV replication,...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Acute lung injury Chemokine CC motif ligand 5 (RANTES; CCL5); platelet factor 4 (PF4; CXCL4) Human and mouse studies suggest inhibiting the CCL5-CXCL4 interaction...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Clinical News

Carolus preclinical data

In mouse models of acute lung injury, CT-2009 disrupted heteromers formed by the platelet-derived chemokines chemokine CC motif ligand 5 ( RANTES ; CCL5 ) and platelet factor 4 ( PF4 ; CXCL4 ) and...